170 related articles for article (PubMed ID: 10146918)
1. Idarubicin: a pharmacoeconomic evaluation of its use in adult patients with acute myeloid leukaemia.
Whittington R; Goa KL
Pharmacoeconomics; 1993 Oct; 4(4):287-307. PubMed ID: 10146918
[TBL] [Abstract][Full Text] [Related]
2. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia.
Bradstock K; Matthews J; Young G; Lowenthal R; Baxter H; Arthur C; Bashford J; Brighton T; Cannell P; Dunlop L; Durrant S; Enno A; Eliadis P; Gill D; Gillett A; Gottlieb D; Januszewicz H; Joshua D; Leahy M; Schwarer A; Taylor K;
Leukemia; 2001 Sep; 15(9):1331-8. PubMed ID: 11516093
[TBL] [Abstract][Full Text] [Related]
3. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
Br J Haematol; 1998 Oct; 103(1):100-9. PubMed ID: 9792296
[TBL] [Abstract][Full Text] [Related]
4. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
5. [Standard-dose of idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukaemia].
Qian SX; Li JY; Wu HX; Lu H; Qiu HX; Chen LJ; Lu RN; Xu W; Sheng RL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):209-13. PubMed ID: 19236781
[TBL] [Abstract][Full Text] [Related]
6. [Improved treatment results in children with AML: Results of study AML-BFM 93].
Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
[TBL] [Abstract][Full Text] [Related]
7. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
Mehta J; Powles R; Singhal S; Horton C; Hamblin M; Zomas A; Saso R; Prendiville J; Glynne P; Allford S; Mackay H; Treleaven J
Semin Hematol; 1996 Oct; 33(4 Suppl 3):18-23. PubMed ID: 8916312
[TBL] [Abstract][Full Text] [Related]
8. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia.
Fedele PL; Avery S; Patil S; Spencer A; Haas M; Wei A
Intern Med J; 2014 Aug; 44(8):757-63. PubMed ID: 24863325
[TBL] [Abstract][Full Text] [Related]
9. Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).
Erba HP; Sayar H; Juckett M; Lahn M; Andre V; Callies S; Schmidt S; Kadam S; Brandt JT; Van Bockstaele D; Andreeff M
Invest New Drugs; 2013 Aug; 31(4):1023-34. PubMed ID: 23397500
[TBL] [Abstract][Full Text] [Related]
10. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
[TBL] [Abstract][Full Text] [Related]
11. [Complete Remission Rate and Adverse Ractions of Three Different Chemotherapy Regimens in the Treatment of Adult Patients with Newly Diagnosed Non-M3 AML].
Lin P; Wang W; Huang WB; Li MW; Yang XN; Yao HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):422-426. PubMed ID: 29665909
[TBL] [Abstract][Full Text] [Related]
12. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
13. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
[TBL] [Abstract][Full Text] [Related]
14. Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies.
Carella AM; Berman E; Maraone MP; Ganzina F
Haematologica; 1990; 75(2):159-69. PubMed ID: 2192943
[TBL] [Abstract][Full Text] [Related]
15. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.
Lee JH; Kim H; Joo YD; Lee WS; Bae SH; Zang DY; Kwon J; Kim MK; Lee J; Lee GW; Lee JH; Choi Y; Kim DY; Hur EH; Lim SN; Lee SM; Ryoo HM; Kim HJ; Hyun MS; Lee KH;
J Clin Oncol; 2017 Aug; 35(24):2754-2763. PubMed ID: 28632487
[TBL] [Abstract][Full Text] [Related]
16. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
Pigneux A; Perreau V; Jourdan E; Vey N; Dastugue N; Huguet F; Sotto JJ; Salmi LR; Ifrah N; Reiffers J
Haematologica; 2007 Oct; 92(10):1327-34. PubMed ID: 18024370
[TBL] [Abstract][Full Text] [Related]
17. High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
Low M; Lee D; Coutsouvelis J; Patil S; Opat S; Walker P; Schwarer A; Salem H; Avery S; Spencer A; Wei A
Intern Med J; 2013 Mar; 43(3):294-7. PubMed ID: 22757980
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloblastic leukaemia--a model for assessing value for money for new treatment programmes.
Lobo PJ; Powles RL; Hanrahan A; Reynold DK
BMJ; 1991 Feb; 302(6772):323-6. PubMed ID: 1900453
[TBL] [Abstract][Full Text] [Related]
19. Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia.
Trifilio S; Zhou Z; Mehta J; Czerniak C; Pi J; Greenberg D; Koslosky M; Pantiru M; Altman J
Leuk Res; 2013 Aug; 37(8):868-71. PubMed ID: 23726414
[TBL] [Abstract][Full Text] [Related]
20. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
